Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta-analysis

INTRODUCTION: Hepatocellular carcinoma (HCC) is the sixth most common cancer globally, and a major unresolved medical issue. According to the guideline recommendations of the European Association for the Study of the Liver in 2018 and the American Society for Clinical Oncology (ASCO) Guideline, nivolumab is a reasonable option for appropriate advanced stage HCC. EVIDENCE ACQUISITION: We searched the PubMed, Embase and CNKI (China National Knowledge Infrastructure) databases for all articles within a range of published years from 2010 to 2020 of nivolumab in advanced hepatocellular carcinoma and carried out this meta-analysis on all published studies to estimate prognostic factors of nivolumab in advanced hepatocellular carcinoma. EVIDENCE SYNTHESIS: Finally, 6 studies with 627 advanced hepatocellular carcinoma patients treated with nivolumab met the inclusion criteria for this study. Our results indicated that alpha-fetoprotein (AFP), eastern Cooperative Oncology Group (ECOG) performance status, Child-Pugh Class, portal vein invasion, protein induced by vitamin K absence-II (PIVKA-II), and albumin-bilirubin (ALBI) score were prognostic factor of nivolumab in advanced hepatocellular carcinoma; however, hepatitis C virus (HBV) infection, Barcelona Clinic Liver Cancer (BCLC) stage, and extrahepatic metastasis were not significant prognostic factors. CONCLUSIONS: Our meta-analysis indicated the potential prognostic factor of nivolumab in advanced hepatocellular carcinoma. However, ongoing clinical and translational research may provide us a better understanding of the prognostic factor and mechanisms. (Cite this article as: Xiong D, Zhang K, Xu M. Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta analysis. Panminerva Med 2023;65:506-10. DOI: 10.23736/S0031-0808.21.04282-8)